Yes. I believe it can, certainly, in cases where the progress of the disease can be measured. I can tell you we are doing it in research systematically.
You know that to be able to prescribe a medication for a patient in Quebec or in British Columbia, the patient must have scored at least 21 out of 30. Then the government will pay. However, if you fall below 10, it will no longer pay. So there are scales. There is a way of quantifying these changes. My short answer is yes.
To add a bit of context, I also work, at the prevention centre I direct, with 400 children of people with Alzheimer's disease who are genetically at high risk of having the disease. The discussion we are having this morning is one I have had with them for a decade. Those situations are very relevant to what you have just raised.